Mitral valve replacement at Tygerberg Hospital: a 5 year follow-up by Barnard, B.J. & le Roux, P.J.
Mitral valve replacement  
at Tygerberg Hospital:  
a 5 year follow-up
mented by patient records from the morgue at Tygerberg Hospital 
and the death register from forensic pathology from the University 
of Stellenbosch. From Jan 1998-Dec 2002, 187 consecutive, iso-
lated mitral valve replacements were done at Tygerberg Hospital. 
Twenty seven patients had incomplete data and they were excluded 
from the study. These patients could not be contacted and 
they were never seen at any follow-up clinic.The follow-up was 
85.56% complete. The average follow-up time was 5.41 years. 
The average age of the patients was 34.86 +/-16.1 years. All 
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MiTrAl vAlvE 
rEplAcEMEnT
Mechanical valve replacement in the mitral position started with 
introduction of cardiopulmonary bypass in 1960. The St Jude 
medical bileaflet mechanical prosthesis was introduced in 1977. It 
has gone through several refinements and is currently the most 
commonly used mechanical valve prosthesis.(1) Structural failure is 
no longer a source of significant morbidity with mechanical pros-
thesis, but thromboembolism and anticoagulant-associated hae-
morrhage remain significant sources of morbidity and mortality. 
Progress has been made with the latest generation bioprosthesis, 
using new fixation and preservation methods. To date long term 
durability of bioprosthetic valves does not approach that of 
mechanical prosthesis.(2) This study was conducted to provide 
midterm follow-up data of isolated mitral valve replacement with 
mechanical prosthesis. We also wanted to identify preoperative 
risk factors for mitral valve surgery.
Methods                                                                          
Data were collected both actively (clinic visits and telephonically) 
and passively (patient files and echocardiographic reports). To 
determine mortality figures, data collected was further supple-
this study provides 5-year follow-up data of isolated mitral 
valve replacements with mechanical prosthesis at a large 
south African tertiary hospital. It also assessed the signi-
ficance of pre-operative parameters to predict mortality. 
this is a retrospective study of 187 patients that underwent 
isolated mitral valve replacement at tygerberg hospital 
from Jan 1998-dec 2002. twenty seven patient’s data was 
incomplete and they were excluded from the study. All 
patients had rheumatic mitral valve disease and the valve 
lesions included mitral incompetence, mitral stenosis and 
mixed mitral valve disease. All patients had a mechanical 
prosthesis implanted (st Jude medical or orbis bileaflet 
valves). the mean follow-up time was 5.41-years. the 30 
day mortality was 5.62% and the 5-year survival was 80%. 
Pre-operative risk factors that significantly increased mor-
tality were pulmonary hypertension and mitral stenosis. 
Valve-related complications were more common in this 
series compared to other First World populations but our 
results compare well with other third World population 
groups. Valve thrombosis 4.32% (0.8%/yr), thromboembo-
lism 8.71% (1.61%/yr), anticoagulant related haemorrhage 
6.87% (1.27%/yr), prosthetic valve endocarditis 3.08% 
(0.57%/yr) and re-operation 8.12% (1.5%/yr). 
conclusion: Mechanical valve replacement for mitral valve 
disease that requires valve replacement is still a good 
treatment option even in third world population groups. In 
our series, severe pulmonary hypertension, mitral stenosis 
and reoperation was statistically significantly more common 
in the “non-survivors” group. SAHeart 2010; 7:30-37
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patients had a mechanical prosthesis implanted (St Jude medical 
or Orbis bileaflet valve) and all patients had rheumatic mitral valve 
disease. Tricuspid valve repair was done in only 4 patients.
Selection criteria were the following:(3)  
Mitral stenosis:   a mean gradient > 12mmHg or valve area  
< 1.5 cm square, in a valve that is not 
suitable for balloon valvuloplasty.
Mitral incompetence: 4+ MI with or without symptoms
  3+ MI with symptoms or LVED that 
progress at follow-up
Endocarditis:  3 or 4+ MI with or without symptoms
                         Uncontrolled sepsis
                         Organism resistant to treatment
                         Annular abscess
                         Intracardial fistula
                         Vegetation >1 cm on valve leaflets
                          Multiple emboli despite appropriate 
antibiotics
Forty seven patients presented with predominantly mitral stenosis, 
55 had mitral incompetence and 39 presented with mixed mitral-
valve disease. Thirteen patients had reoperations during the study 
period. Standard echocardiographic assessment was performed 
on all patients and included left ventricular end-diastolic dimension 
(LVED), left atrial dimension (LA), ejection fraction (EF) and pul-
monary artery pressure (Table 1).
oPerAtIVe technIques                                                 
All operations were performed with cardiopulmonary bypass and 
had moderate hypothermia (30-32 degrees Celsius).The ascending 
aorta was cannulated and bicaval venous cannuli was used. Cold 
crystalloid cardioplegic solution was administered via the aortic 
root every 20 minutes. Topical pericardial cooling was also done 
for extra myocardial protection. Mitral valve replacement was 
performed with single pledgeted sutures in the annules and a left 
ventricular vent was placed trough the mitral valve before the 
atrium was closed. Emergency reoperations were done in 3 cases 
via right thoracotomy with cannulation of the femoral artery and 
right atrium. Surgery was done under CO2 field on a beating heart.
All the chordae were resected with the stenotic valves and the 
posterior leaflet and chordae was not resected during replacement 
of incompetent valves.
post-operative management
Subcutaneous Heparin was started as soon as mediastinal drain- 
age stopped. All patients were started on Warfarin day 1 post 
operatively and Heparin was stopped when the INR reached 2-4. 
The average follow-up time was 5.41 years. Patients were asked 
to return to the clinic at 1.3 and 6 months post-operatively and 
then every 6 months. Monthly INR readings were done at their 
local clinics and the Warfarin dose was adjusted accordingly.
tAbLe 1:  patient profile according to echocardiographic findings.  The table indicates the percentages of the total number of patients for each echo-
cardiographic parameter
EF <50% 50-60% 60-70% 70-80% 
 3.6% 20.85% 46.62% 28.83% 
LVED <45mm 46-55mm 56-65mm 66-75mm >75mm
 16.18% 39.88% 28.32% 13.29% 2.31%
LA <45mm 46-55mm 56-65mm 66-75mm >75mm
 17.34% 43.35% 27.16% 8.67% 3.46%
Pulmonary pressure <30mmHg 30-39mmHg 40-49mmHg 50-59mmHg >60mmHg
 24.02% 17.54% 14.93% 14.28% 29.22%
EF: ejection fraction, LVED: left ventricular end-diastolic dimension, LA: left atrium.
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deFInItIons And dAtA AnALysIs(4)                        
Mortality
30 day mortality is death within 30 days of surgery irrespective 
of where the patient might be.
5 year survival is the total amount of patients that was alive at 
average 5 years post-operatively.
Late mortality is death after 30 days and before 10 years post- 
operatively.
valve-related mortality
Valve-related mortality included valve complications that resulted 
in the late death of the patient.
non-structural valve dysfunction
This is incompetence or stenosis which was not caused by intrinsic 
valve dysfunction as diagnosed by reoperation, autopsy, or clinical 
investigation (infection and thrombosis excluded).
Example: pannus, paravalvular leak, clinically important intravas- 
cular haemolytic anaemia, inappropriate sizing or positioning.
valve thrombosis
Any thrombi stuck to or close to the prosthesis which influences 
the normal functioning of the valve or is sufficiently large to warrant 
treatment. Valve thrombus found at autopsy in a patient whose 
cause of death was not valve-related or found at operation for 
an unrelated indication should also be counted as valve throm-
bosis. Infection excluded.
Thromboemboli
Any embolic event that occurs in the absence of infection after the 
immediate preoperative period. It may be manifested by a neuro-
logical event or non cerebral embolic event.
cerebrovascular incident
Is a prolonged (>72h), or permanent neurological deficit that is 
usually associated with abnormal results of magnetic resonance 
imaging or computed topographic scans. Patients with minimal, 
atypical, or protean symptoms that lead to radiographic imaging 
■
■
■
demonstrating an acute ischaemic event are considered to have 
sustained a stroke.
Bleeding
Any internal or external bleeding that leads to transfusion, hos-
pitalisation, permanent damage or death. Major bleeding unex- 
pectedly associated with minor trauma should be reported as a 
bleeding event but bleeding associated with major trauma or 
major operation should not.
valve endocarditis
Diagnosis is based on the following criteria: (1) Reoperation with 
evidence of abscess, paravalvular leak, pus, or vegetation con- 
firmed as secondary to infection by histologic or bacteriologic 
studies. (2) Autopsy findings of abscess, pus, or vegetation involving 
a repaired or replaced valve.(3) In the absence of reoperation or 
autopsy, meeting of the Duke criteria for endocarditis.(4) Positive 
blood cultures are not required for the diagnosis of operated valve 
endocarditis. Culture negative endocarditis refers only to negative 
blood culture results and not just the absence of any proof of 
infection.
Data was entered into a Excel spreadsheet. Statistical analysis was 
performed using the NCSS 2004 statistical package. (Number 
Crucher Statistical Systems, Kaysville Utah).
Data was tested for normality using Kolmogorov-Smirnov Test. 
Parametric data was analysed using students T-test and Kruskal-
Wallis one-way ANOVA on ranks. Post-hoc analysis of differences 
between groups was performed using Tukey-Kramer Multi-Com-
parison Test. Non-parametric data was analysed with Mann- 
Whitney U or Wilcoxon Rank-Sum Test. Proportions were com-
pared using Chi square (Fishers exact test). Survival was plotted 
using Kaplan Meier-curves. Logistical regression was performed. 
This was done to evaluate the pre-operative risk factors. P-value 
of 0.05 was considered significant.
resuLts                                                                               
The 30 day mortality was 5.62% (9 patients) as shown in Table 2. 
The most common cause for early mortality was low cardiac out-
put in the ICU; others include pneumonia and renal failure. 
MiTrAl vAlvE rEplAcEMEnT
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Late death occurred in 14.37% (23 patients) as shown in Table 3.
At 5 years the estimated survival was 80% (Figure 1).
Valve-related mortality, shown in Table 4, resulted in 5 year free-
dom from valve-related mortality of 92.5%. This figure changes to 
83.75% if unknown causes of death are included.
Figure 1 shows the Kaplan Meier survival curve with 95% confi-
dence intervals.
Thirteen patients required reoperation during the study period, 
shown in Table 5. The 30 day mortality for elective reoperation 
was 0% and the 30 day mortality for emergency re-operations 
was 57.14% and the 5 year freedom from reoperation was 
91.87%.
The following pre-operative echocardiographic parameters were 
evaluated:  LVEF, LVED, LA (diameter), PA pressure and valve 
lesions, (mitral incompetence, mitral stenosis and mixed mitral 
valve disease) (Table 1). In our series, the average pulmonary 
pressure was statistically, significally higher in the non-survivors 
compared to survivors.  We also found that mitral stenosis was a 
significant risk factor for 5 year mortality.  This is shown in Table 6.
Morbidity
1.25% of patients needed a resternotomy for post-operative 
bleeding and 1.25% of patients developed sternal sepsis post- 
operatively.  
tAbLe 2:  Early mortality,  from the day of surgery to 30 days post- 
operatively 
cause of death rate as % of total  number of patients
 nr of patients
Low cardiac output in ICU 4.37% 7
Pneumonia 0.62% 1
Renal failure 0.62% 1
tAbLe 3:  late mortality, from 1 month post operative to the 
maximum of 9.58 years
cause of death rate as % of total  number of patients
 nr of patients
Unknown 8.75% 14
Stroke 3.75% 6
Heart failure 1.25% 2
Heart block 0.62% 1
Su
rv
iv
al
1 000
750
500
250
0
0.0
FIGure 1: Showing the Kaplan Meier survival curve with 95% 
confidence intervals
Follow up years
2.5 5.0 7.5 10.0
tAbLe 4:  valve related mortality
cause of death rate as % of total  number of
 nr of patients patients
Thromboembolism 3.75% 6
Thrombotic valve obstruction 2.5% 4
Prosthetic valve endocarditis 1.25% 2
Total 7.5%* 12
*If unknown causes of death are presumed to be valve related, total valve related mortality 
would be 16.25%.
tAbLe 5:  reoperation during the study period
indication rate as % of total  number of patients
 nr of patients
Clotted valves 4.37% 7
Pannus ingrowth 1.25% 2
Bacterial endocarditis 1.25% 2
Paravalvular leaks 1.25% 2
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tAbLe 6:  pre-operative risk factors that were tested are shown in Table 6. Statistically significant risk factors to predict 5 year mortality are indicated by *
tAbLe 7:  Major valve related events at Tygerberg Hospital compared to two other University hospitals from first world countries. 
valve related events  Tygerberg Hospital Switzerland Univ Basel(6) Tokyo Japan(7)
Structural valve degeneration 0 0 0.24 %/yr
Non-structural valve dysfunction:  0.1-0.6 %/yr 0.06 %/yr
Pannus 0.23 %/yr  
Paravalvular leaks 0.8 %/yr  
Valve thrombosis 0.8 %/yr 0.9 %/yr 0.39 %/yr
Emboli 1.61 %/yr 0.9 %/yr 0.39 %/yr
Bleeding 1.27 %/yr 0.5 %/yr 0.39 %/yr
Bacterial endocarditis 0.57 %/yr 0.03 -0.1 %/yr 0
Stroke 1.61 %/yr - -
Atrial fibrillation: Pre-op 32.5 % - 
                        Post-op 5.6 % - 
parameter Survivors non-survivors p-value
Redo-surgery 7 (5.9%) 6 (23.1%) 0.013*
Ejection fraction 64.4 + 8.1 68.0 +7.5 0.399
Mean + standard deviation
LVED 55.9 + 9.9 55.0 + 10.3 0.857
Mean + standard deviation
LA 53.6 + 8.6 55.2 + 10.3 0.957
Mean + standard deviation 
Pulmonary pressure 46 (42-51) 63 (54-78) 0.002*
Median + 95% confidence interval
Valve lesion 35 (29.9%) 12 (50.0%) 0.041*
MS 
Age at surgery 33.5 + 15.2 38.7 +18.6 0.215
Mean + standard deviation
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Valve-related events are shown in Table 7.  This was compared to 
similar events in other series(5,6,7) of well controlled First World 
populations. A third of pre-operative patients were in atrial 
fibrillation but no atrial ablations were done for atrial fibrillation.
dIscussIon                                                                     
Mechanical valve replacement places huge responsibility on the 
patient and the medical system of a country.  Poor compliance 
with post-operative therapy, especially anticoagulation, constitutes 
a significant hazard for patients with mechanical prosthesis.(8) For 
any type of prosthesis, patient compliance with anticoagulation is 
the most important determinant of thrombosis and thrombo-
embolism.(9,10)  The majority of our patients live under poor socio-
economic conditions and consequently, thrombotic and throm-
boembolic rates were expected to be higher than those in First 
World countries.  Although this proved to be the case, the numbers 
were lower than anticipated and compared very well with other 
Third World population groups.(11)  The 27 patients lost to follow- 
up could be a significant factor in the interpretation of the data. If 
all those patients are presumed non-survivors during the study 
period, the 5 year survival would change from 80% to 68.45%.
These patients were lost to follow-up at any clinic and could not 
be contacted. This included checking patient folders, clinic records, 
phoning listed telephone numbers and searching the morgue 
records and death register at our institution. 
throMboeMboLIsM                                                      
Systemic thromboembolism is a major cause of morbidity in 
patients with mechanical valves. The thromboembolism incidence 
for mitral valve replacement with the St Jude medical prosthesis 
is 2.7% /pt-year according to M.J. Antunes,(12) in other First World 
countries like Switserland and Japan, shown in Table 7, the inci- 
dence was 0.9% and 0.39% respectively. In our series the incidence 
of thromboembolism was 1.61% /pt-year (14 patients). Three of 
these patients (21.42%) were known to be in atrial fibrillation, 
although this is surprisingly few, some authors have found no 
correlation between atrial fibrillation and the increased risk of 
thromboembolism in patients with mechanical prosthesis.(13,14)
throMbotIc VALVe obstructIon                          
In this series thrombotic obstruction occurred in 4.37% of 
patients, this is 0.8%/year and calculates to 95.63%, 5 year free- 
dom from thrombotic obstruction. This is higher compared to the 
0.1%/pt-year in other studies.(12) The reason for this is poor con- 
trol of anticoagulation. On admission, six of the patients had an 
INR value of less than 2 and only one patient had an INR of 2.5. 
Thrombolysis should be considered in these patients with some 
authors reporting good results with double-disc prosthesis. The 
results after a 42 month period show a 5.8% mortality, 67% free 
from rethrombosis, and 17.6% embolic complications in some 
studies.(15) At Tygerberg Hospital a study was done that docu- 
mented the diagnosis and management of prosthetic valve ob- 
struction.(24) A total of 6 patients received thrombolitic therapy 
and 4 of these patients were considered too ill for surgery. 
Four patients (66,6%), of the thrombolitic group died. The authors 
proposed that thrombolitic therapy should be considered in 
patients that are poor surgical candidates. For example patients in 
cardiogenic shock, NYHA 4, and patients with co-morbidities.
AntIcoAGuLAnt–reLAted hAeMorrhAGe        
The incidence of anticoagulant-related haemorrhage is a function 
of intensity of anticoagulation.(13,16) This complication occurred in 
6.87% of patients (1.27%/year). Of  these patients, 45% had a 
INR level of less than 2 and in 27% of cases the INR values were 
> 10, another 27% of patients had no INR values available at the 
time. Other studies have reported bleeding events of up to 4.3%/
pt-year in Third World population groups.(13,10,17,18,19,20) Antunes 
showed bleeding events of 0, 7%/pt year, which is low for a 
Third World population group, but could possibly be related to 
a lower level of compliance.(11) First World populations like 
Switzerland(6) and Japan(7) report the incidence of this complication 
as 0.5%/year and 0.39%/year respectively.
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reoPerAtIon                                                                     
A total of 13 reoperations were performed.  The 30 day mortality 
for reoperation was 30.76%.  This is higher than in other studies 
looking at Third World population groups.(11) Reoperation was 
found to be a statistically significant risk factor for 5 year morta- 
lity.  The reason for this is that 7 of the patients were done as 
emergencies with clotted valves. The 30 day mortality of the 
emergencies was 57.14% and the 30 day mortality of the elective 
reoperations was 0%. Two of the elective patients died during 
the follow-up period and the 5 year survival of reoperation cal-
culated to 46.15%. We have changed our approach to the emer-
gency surgery (from 2001) and 2 of these patients were done 
through a right thoracotomy, on a beating heart and femoral by-
pass, in a carbon dioxide field. These  patients both survived.
ProsthetIc VALVe endocArdItIs                              
This complication occurred in 3.12% of cases (0.57%/year). This 
is high compared to other series of First World population groups 
(0.03-0.1%/year)(5,6,7) and even Third World population studies 
report an incidence of 0.2%/pt-year.(11) A possible explanation 
for this is the high incidence of pre-operative bacterial endocar- 
ditis (16.25%). 
PuLMonAry hyPertensIon                                     
Pulmonary pressure was statistically significantly higher in the 
non-survivor group 54 to 78 mmHg (mean 63mmHg) versus 
the survivor group 42 to 51mmHg (mean 46mmHg). This data is 
supported by the data reported by Cesnjevar(21) who found that 
with a mean PA pressure of > 50mmHg, post-operative mortality 
is higher (8.6% - 13.7%), depending on the patients age, compared 
to patients without pulmonary hypertension (3.6%).  One way of 
predicting post-operative problems with the right ventricle is to 
measure tricuspid valve annular shortening, echographically. If this 
is < 11% it was associated with adverse outcome.(22) Mitral valve 
replacement should still be offered, albeit with a higher risk, even 
in the presence of severe pulmonary hypertension as long as 
pulmonary pressures are below systemic pressure.(23)
MiTrAl vAlvE rEplAcEMEnT
MItrAL stenosIs                                                             
The reason why mitral stenosis was a risk factor for 5 year morta-
lity is still unknown. One possible explanation for this can be the 
loss of all chordae during valve excision. 
This study suffers from a number of weaknesses inherent to a 
retrospective study including incomplete follow-up data (85% 
complete).  The INR values of all the patients were not included 
pre-operatively and at follow-up and there was no data available 
to indicate the incidence of pregnancy and human immune 
deficiency virus in patients with prosthetic valve replacement.
concLusIon                                                                     
Thrombotic obstruction and thromboembolism is higher in a 
Third World population. Significant bleeding episodes, valve endo-
carditis and non-structural valve degeneration, were also more 
common in our study, compared to other First World studies.(5,6,7) 
Even with the higher morbidity, this study showed an acceptable 
5 year post-operative survival. Mechanical valve replacement in 
the mitral position is still a good option in the younger population, 
even in a developing country. Pre-operative risk factors predicting 
5 year mortality in our study were high pulmonary pressure, pure 
mitral stenosis and reoperation.
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